Kevin McCulloch - 01 Aug 2024 Form 3 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
01 Aug 2024
Net transactions value
$0
Form type
3
Filing time
02 Aug 2024, 17:16:53 UTC
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XERS Common Stock 1,451,953 01 Aug 2024 Direct F1
holding XERS Common Stock 25,000 01 Aug 2024 By Spouse F2
holding XERS Common Stock 2,000 01 Aug 2024 Charles R. McCulloch Trust dated 1990 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XERS Stock Option (Right to Buy) 01 Aug 2024 Common Stock 92,667 $4.09 Direct F3
holding XERS Stock Option (Right to Buy) 01 Aug 2024 Common Stock 80,000 $3.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes common stock purchased on the open market, unvested restricted stock units ("RSUs") and shares received upon vesting of RSUs, net of shares withheld for tax, and shares acquired under the Company's 2018 Employee Stock Purchase Plan.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 These options are fully vested as of the date hereof.

Remarks:

President and Chief Operating Officer